Read more
The renowned authors of this ECFR special volume systematically develop legal standards and regulatory frameworks for closed corporations in Europe (including of course the Societas Privata Europaea), putting a strong focus on the economic practice and efficiency. The profound, in-depth analysis of the objectives and strategies comes to groundbreaking insights and also offers specific solutions for a multitude of practical aspects.
About the author
Andreas Engert M.D. is Professor for Internal Medicine, Hematology and Oncology. He received his medical degree at the University of Hannover and had his medical training at the University of Hannover and the University Hospital of Cologne. Between 1988 and 1990 he worked at the Imperial Cancer Research Fund in London on new immunotherapeutic approaches for cancer. After returning to Cologne, he and his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma resulting in a number of experimental phase I/II clinical trials. He finished his postdoctoral lecture qualification in 1995, was appointed consultant and became head of staff 1996. He was appointed coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology in 2000. After Serving as Secretary of the German Hodgkin Study Group (GHSG) since 1999, Prof. Engert was elected GHSG chairman in 2007. For his scientific work, he has received numerous awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award and the Research Award of the University of Cologne.§The focus of his research for many years has been the development of targeted therapy to combat malignancy. Activities include constructs such as bispecific monoclonal antibodies, radioimmunoconjugates, humanized antibodies or immunoligands for diseases such as neuroblastoma, chronic lymphocytic, acute leukemias and malignant lymphoma. Prof. Engert treats patients with all malignancies and consults for lymphoma patients. In addition he is active in the field of evidence-based medicine as editor of the Cochrane Review Group for Hematological Malignancies (CHMG).§The clinical focus of his work is the German Hodgkin Study Group (GHSG) with all of its different facets including planning and conducting clinical trials of all phases. The GHSG has conducted more than 20 randomized studies with more than 20.000 patients overall registered and is actively involved in a number of early clinical trials evaluating new drugs for patients with Hodgkin Lymphoma.
